Approach to the Treatment of Spontaneous

Total Page:16

File Type:pdf, Size:1020Kb

Approach to the Treatment of Spontaneous Olgu Sunumu Sakarya 193 Case Report Medical Journal doi:10.5505/sakaryamj.2012.19483 Approach To The Treatment of Spontaneous Hemothorax Due To The Anticoagulant Therapy: Report of Three Cases Antikoagülan Tedaviye Bağlı Gelişen Spontan Hemotoraksta Tedavi Yaklaşımı: Üç Olgu Sunumu Yener Aydın1, Murat Aydın2, Hasan Kaynar3, Atila Türkyılmaz1, Atilla Eroğlu1 1 Department of Thoracic Surgery, Ataturk University, Medical Faculty, Erzurum, Turkey 2 Yozgat State Hospital, Department of Cardiovasculer Surgery, Yozgat, Turkey 3 Department of Chest Diseases, Ataturk University, Medical Faculty, Erzurum, Turkey Abstract Özet Bleeding is the most important complication of the anticoagulant the- Antikoagülan tedavinin en önemli komplikasyonu kanamadır. Warfarin rapy. The annual risk of bleeding in patients taking warfarin such as; alan hastalarda yıllık kanama riski; fatal epizod yaklaşık %1, major fatal episode is approximately 1%, major episode is 6.5%, and minor epizod %6.5, minör kanama ise %21.8’dir. Literatürde antikoagülan bleeding is 21.8%. A small number of hemothorax cases that formed tedaviye bağlı az sayıda spontan hemotoraks olgusu bildirilmiştir. due to anticoagulant therapy, have been reported in the literature. Kanama şiddetli ise şok ve mortalite gelişebilir. Hemotoraks yeterli Shock and mortality may be developed in severe bleeding. Hematoma şekilde boşaltılmazsa hematom ve hapsolmuş akciğer oluşumu riski and trapped lung may be occurred, if hemothorax not adequately disc- taşımaktadır. Hemotoraks görüldüğünde antikoagülan tedavi hemen harge. When the hemothorax is seen, anticoagulant therapy should sonlandırılmalı ve plevral aralık boşaltılmalıdır. Bu çalışmada warfarin be terminated immediately and pleural range to be discharged. In pre- tedavisine bağlı üç olguda gelişen spontan hemotoraks olgusu literatür sent study, three cases were presented with the literature, which had bilgileri ışığında sunuldu. detected spontaneous hemothorax due to the anticoagulant therapy during the warfarin therapy. Keywords: Anticoagulation, spontaneous hemothorax, treatment Anahtar Kelimeler: Antikoagülanlar; hemotoraks, tedavi Aplication: 14.09.2011 Accepted: 14.11.2011 Başvuru Tarihi: 14.09.2011 Kabul Tarihi: 14.11.2011 Introduction getting anticoagulant and neoplasm. Rare reasons are vascular ruptures such as aortic dissection and arterio- The hemothorax that occurred without any specific tra- venous fistulas, pulmonary infarction, rupture of pleural uma, denominated spontaneous or nontraumatic he- adhesions due to pneumothorax, pleural endometriosis, mothorax. Although spontaneous hemothorax rarely haemophilia, thrombocytopenia and the other conditions than traumatic hemothorax it have lots of causations. that change the homeostasis and idiopathic situations 1. The main causation of the spontaneous hemothorax is The annual risk of bleeding in patients taking warfarin Yazışma Adresi/Corresponding to: Yard. Doç. Dr. Yener Aydın, Atatürk Üniversitesi Tıp Fakültesi Göğüs Cerrahisi AD, 25240 Erzurum - Türkiye GSM : 05357848970, e-mail: [email protected] Aydın ve Ark. 194 Spontaneous Hemothorax Due to the Anticoagulant Therapytherapy Sakaryamj 2012;2(4):193-196 such as; fatal episode is approximately 1%, major episo- thoracostomy was applied six hour later. 600cc drainage de is 6.5%, and minor bleeding is 21.8%2. It is classified was observed. Streptokinase is administered within the as major if it is intracranial or retroperitoneal and hospita- pleural hematoma. After the third day of tube thoracos- lization or transfusion can be required or it can cause di- tomy, streptokinase (150.000 IU) was diluted in 100 ml rectly mortality3. Although the anticoagulant therapy has of saline and applied to the intrapleural space through frequently using, a small number of cases have been re- the thorax tube during three days. After the intrapleu- ported with hemothorax due to anticoagulant therapy in ral fibrinolytic treatment (IPFT), it was detected that the the literature. In this study, the three cases are presen- decreasing pleural thickening and adhesion with the re- ted, that have detected spontaneous hemothorax due to solution of the clots in the pleural range. The patient was warfarin therapy. discharged without need of any other treatment. Case I Case III A 26-year-old male patient, which had detected deep A 50-year-old male patient admitted to our clinic with venous thrombosis in Doppler ultrasound application for complaint of right chest pain and dyspnea. He had a right leg pain. Warfarin treatment was started. Left chest history of coronary bypass surgery and mitral valve rep- pain was occurred in the eight day of the treatment. In lacement one year ago. INR was detected as 3.5 and physical examination revealed reduced breath sounds in haemoglobin was detected as12.6 g/dL in patient taking left lung. Posterior-anterior (PA) chest radiography revea- warfarin. Thorax CT revealed pleural fluid and extensive led pleural fluid in left lung. Contrasted thorax computed pleural thickening. Also warfarin was discontinued im- tomography (CT) viewed 6 cm thickness pleural effusi- mediately. K vitamin was given and three units of fresh on in the left thorax and formation of fibrotic bands and frozen plasma were transfused. Right tube thoracos- linear atelectasis in the basalis of left lung. No embo- tomy was applied one day later. 800 cc drainage was lism was observed. Haemoglobin was found 13.4 g/dL observed. Streptokinase (150.000 IU) was diluted in 100 (normal values range from 14 to 16 g/dL), international ml of saline and applied to the intrapleural space through normalized ratio (INR) was found 12.48 in laboratory exa- the thorax tube during three days as case 2. However mination. Warfarin was stopped immediately. Two units the decreasing pleural thickening and adhesion could not of fresh frozen plasma were transfused. K vitamin supp- obtained with the resolution of the clots in the pleural lement were given. Tube thoracostomy was applied se- range. Decortication was suggested in this case. But, cond day. 700cc hemorrhagic drainage was observed. the patient was not accepted surgery. The fluid was completely drained through the chest dra- in. Additional process did not apply. After third day, the Discussion thorax drain was ended and the patient was discharged. The complication of the anticoagulant therapy for the Case II pulmonary embolism is the one of the most common known causes of spontaneous hemothorax4. There have A 50-year-old male patient was admitted to our clinic well documented 20 cases with spontaneous hemot- with complaint of chest pain and coughing. He had a his- horax due to the anticoagulant therapy5. Rostant et al6. tory of aortic and mitral valve replacement six mounts Were reported 11 cases with hemothorax due to the ago. Patients were receiving warfarin. PA chest radiog- anticoagulant therapy complication. The five of the re- raphy revealed pleural fluid. Haemoglobin was found ported cases had a history of only heparin usage, four 11.4 g/dL. INR was found 2.8 in laboratory examination. had a history of heparin and warfarin usage, and two had Warfarin was ended immediately. K vitamin was given. a history of only warfarin usage. They reported that the Two units of fresh frozen plasma were transfused. Tube hemothorax was occurred usually 4 to 7 day after the an- Aydın ve Ark. Sakaryamj 2012;2(4):193-196 Spontaneous Hemothorax Due to the Anticoagulant Therapytherapy 195 ticoagulant theraphy. Usually dosage was in the therape- that developed due to anticoagulant theraphy for the pul- utic range in these patients and hemothorax was found monary embolism and the four of the reported 20 case in the side of pulmonary embolism. However, recently, was died5. Rupture of pulmonary infarct should be sus- spontaneous hemothorax cases were reported due to pected when the circulatory and respiratory failure with the low molecular weight heparins4,7. Half of enoxapa- unilateral pleural effusion occurred suddenly after the rine associated major bleeding complications had seen 7-10 days from the anticoagulant theraphy in the pati- after the third day of theraphy8,9. We detected three ca- ents with suspected or precised pulmonary embolism10. ses with hemothorax due to oral anticoagulant theraphy There was deep venous thrombosis in our case and any in our study. One of the patients had a history of deep pulmonary embolism was not detected. Hemothorax venous thrombosis and two of them had artificial valve was occurred in eighth day in this case. replacement history. Successful treated cases were reported with thorasyn- Figure 1: Posteroanterior chest radiography of case 1 thesis or tube thoracostomy in literature11-13. Promisloff showing pleural fluid in left lung. 11 described the tube drainage without surgical explora- tion applied. Dimitri12 could not be detected pathology and bleeding focus with thoracoscopic exploration after tube thoracostomy in a patient with massive idiopathic hemothorax. Yung et al.13 were discharged two liters of blood to the pleural space with thoracostomy in a case with spontaneous hemothorax. However they could not be detected bleeding focus and patient treated with tho- rax tube. Figure 2: Thorax CT revealed showing pleural fluid and extensive pleural thickening of case 3.. The anticoagulation effects of warfarin can be reversed by four ways. These are; end the treatment; K vitamin replacement; infusion of fresh frozen plasma (FFP); and infusion of concentrated thrombotic factors2. Usually the effects
Recommended publications
  • Pleural Effusion and Ventilation/Perfusion Scan Interpretation for Acute Pulmonary Embolus
    ventricular function by radionuclide angiography during exercise in normal subjects 33. Verani MS. Myocardial perfusion imaging versus two-dimensional echocardiography: and patients with chronic coronary heart disease. J Am Coll Cardiol 1983;1:1518- comparative value in the diagnosis of coronary artery disease. J NucíCardiol 1529. 1994;1:399-414. 29. Adam WE. Tarkowska A, Bitter F, Stauch M, Geffers H. Equilibrium (gated) 34. Foster T, McNeill AJ, Salustri A, et al. Simultaneous dobutamine stress echocardiog radionuclide ventriculography. Cardiovasc Radial 1979;2:161-173. raphy and technetium-99m SPECT in patients with suspected coronary artery disease. 30. Hurwitz RA, TrêvesS, Kuroc A. Right ventricular and left ventricular ejection fraction J Am Coll Cardiol I993;21:1591-I596. in pediatrie patients with normal hearts: first pass radionuclide angiography. Am 35. Marwick TH, D'Hondt AM, Mairesse GH, Baudhuin T, Wijins W, Detry JM, Meiin Heart J 1984;107:726-732. 31. Freeman ML, Palac R, Mason J, et al. A comparison of dobutamine infusion and JA. Comparative ability of dobutamine and exercise stress in inducing myocardial ischemia in active patients. Br Heart J 1994:72:31-38. supine bicycle exercise for radionuclide cardiac stress testing. Clin NucíMed 1984:9:251-255. 36. Senior R, Sridhara BS, Anagnostou E, Handler C, Raftery EB, Lahiri A. Synergistic 32. Cohen JL, Greene TO, Ottenweller J, Binebaum SZ, Wilchfort SD, Kim CS. value of simultaneous stress dobutamine sestamibi single-photon-emission computer Dobutamine digital echocardiography for detecting coronary artery disease. Am J ized tomography and echocardiography in the detection of coronary artery disease.
    [Show full text]
  • Diagnosing Pulmonary Embolism M Riedel
    309 Postgrad Med J: first published as 10.1136/pgmj.2003.007955 on 10 June 2004. Downloaded from REVIEW Diagnosing pulmonary embolism M Riedel ............................................................................................................................... Postgrad Med J 2004;80:309–319. doi: 10.1136/pgmj.2003.007955 Objective testing for pulmonary embolism is necessary, embolism have a low long term risk of subse- quent VTE.2 5–7 because clinical assessment alone is unreliable and the consequences of misdiagnosis are serious. No single test RISK FACTORS AND RISK has ideal properties (100% sensitivity and specificity, no STRATIFICATION risk, low cost). Pulmonary angiography is regarded as the The factors predisposing to VTE broadly fit Virchow’s triad of venous stasis, injury to the final arbiter but is ill suited for diagnosing a disease vein wall, and enhanced coagulability of the present in only a third of patients in whom it is suspected. blood (box 1). The identification of risk factors Some tests are good for confirmation and some for aids clinical diagnosis of VTE and guides decisions about repeat testing in borderline exclusion of embolism; others are able to do both but are cases. Primary ‘‘thrombophilic’’ abnormalities often non-diagnostic. For optimal efficiency, choice of the need to interact with acquired risk factors before initial test should be guided by clinical assessment of the thrombosis occurs; they are usually discovered after the thromboembolic event. Therefore, the likelihood of embolism and by patient characteristics that risk of VTE is best assessed by recognising the may influence test accuracy. Standardised clinical presence of known ‘‘clinical’’ risk factors. estimates can be used to give a pre-test probability to However, investigations for thrombophilic dis- orders at follow up should be considered in those assess, after appropriate objective testing, the post-test without another apparent explanation.
    [Show full text]
  • An Interesting Case of Undiagnosed Pleural Effusion Case Report
    Amit Panjwani, Thuraya Zaid [email protected] Pulmonary Medicine, Salmaniya Medical Complex, Manama, Bahrain. An interesting case of undiagnosed pleural effusion Case report Pleural effusions are commonly encountered in the Investigations revealed a haemoglobin level Cite as: Panjwani A, Zaid T. clinical practise of both respiratory and nonrespiratory of 16.4 g⋅dL−1, and total leukocyte count of An interesting case of specialists. An estimated 1–1.5 million new cases in 8870 cells⋅mm−3 with a differential count of 62% undiagnosed pleural effusion. the USA and 200 000–250 000 new cases of pleural neutrophils, 28% lymphocytes, 7% monocytes, 2% Breathe 2017; 13: e46–e52. effusions are reported from the UK each year [1]. eosinophils and 1% basophils. The platelet count Analysis of the relevant clinical history, physical was 160 000 cells⋅mm−3. Creatinine, electrolytes examination, chest radiography and diagnostic and liver function tests were normal. The ECG was thoracentesis is useful in identifying the cause of unremarkable and cardiac enzymes were within pleural effusion in majority of the cases [2]. In a few normal limits. Chest radiograph (figure 1) showed a cases, the aetiology may be unclear after the initial mild, right-sided pleural effusion, blunting of the left assessment. The list of diseases that may account for costophrenic angle, no shift of mediastinal position a persistent undiagnosed pleural effusion is long [3]. and no lung parenchymal opacities. We present an interesting case of undiagnosed pleural effusion that was encountered in our hospital. R Case presentation A 33-year-old male presented to our hospital with a history of sudden-onset, pleuritic, right-sided chest pain of 2 days’ duration.
    [Show full text]
  • Diagnosis of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism
    Early View Review Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism Fredrikus A. Klok, Francis Couturaud, Marion Delcroix, Marc Humbert Please cite this article as: Klok FA, Couturaud F, Delcroix M, et al. Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Eur Respir J 2020; in press (https://doi.org/10.1183/13993003.00189-2020). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©ERS 2020 Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism Fredrikus A. Klok, Francis Couturaud F2, Marion Delcroix M3, Marc Humbert4-6 1 Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands 2 Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Univ Brest, EA 3878, CIC INSERM1412, Brest, France 3 Department of Respiratory Diseases, University Hospitals and Respiratory Division, Department of Chronic Diseases, Metabolism & Aging, KU Leuven – University of Leuven, Leuven, Belgium 4 Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France 5 Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France 6 INSERM UMR S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France Corresponding author: Frederikus A. Klok, MD, FESC; Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands; Albinusdreef 2, 2300RC, Leiden, the Netherlands; Phone: +31- 715269111; E-mail: [email protected] Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe long-term complication of acute pulmonary embolism (PE).
    [Show full text]
  • Acute Pulmonary Embolism in Patients with and Without COVID-19
    Journal of Clinical Medicine Article Acute Pulmonary Embolism in Patients with and without COVID-19 Antonin Trimaille 1,2 , Anaïs Curtiaud 1, Kensuke Matsushita 1,2 , Benjamin Marchandot 1 , Jean-Jacques Von Hunolstein 1 , Chisato Sato 1,2, Ian Leonard-Lorant 3, Laurent Sattler 4 , Lelia Grunebaum 4, Mickaël Ohana 3 , Patrick Ohlmann 1 , Laurence Jesel 1,2 and Olivier Morel 1,2,* 1 Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, 67000 Strasbourg, France; [email protected] (A.T.); [email protected] (A.C.); [email protected] (K.M.); [email protected] (B.M.); [email protected] (J.-J.V.H.); [email protected] (C.S.); [email protected] (P.O.); [email protected] (L.J.) 2 INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, 67000 Strasbourg, France 3 Radiology Department, Nouvel Hôpital Civil, Strasbourg University Hospital, 67000 Strasbourg, France; [email protected] (I.L.-L.); [email protected] (M.O.) 4 Haematology and Haemostasis Laboratory, Centre for Thrombosis and Haemostasis, Nouvel Hôpital Civil, Strasbourg University Hospital, 67000 Strasbourg, France; [email protected] (L.S.); [email protected] (L.G.) * Correspondence: [email protected] Abstract: Introduction. Acute pulmonary embolism (APE) is a frequent condition in patients with Citation: Trimaille, A.; Curtiaud, A.; COVID-19 and is associated with worse outcomes. Previous studies suggested an immunothrombosis Matsushita, K.; Marchandot, B.; instead of a thrombus embolism, but the precise mechanisms remain unknown.
    [Show full text]
  • COVID-19 Associated Pulmonary Embolism in Pediatric Patients
    Prepublication Release A N O F F I C I A L J O U R N A L O F T H E A M E R I C A N A C A D E M Y O F P E D I A T R I C S COVID-19 Associated Pulmonary Embolism in Pediatric Patients Melissa Chima, Duane Williams, Neal J. Thomas, Conrad Krawiec DOI: 10.1542/hpeds.2021-005866 Journal: Hospital Pediatrics Article Type: Original Article Citation: Chima M, et al. COVID-19 Associated Pulmonary Embolism in Pediatric Patients. Hosp Pediatr. 2021; doi: 10.1542/hpeds.2021-005866 This is a prepublication version of an article that has undergone peer review and been accepted for publication but is not the final version of record. This paper may be cited using the DOI and date of access. This paper may contain information that has errors in facts, figures, and statements, and will be corrected in the final published version. The journal is providing an early version of this article to expedite access to this information. The American Academy of Pediatrics, the editors, and authors are not responsible for inaccurate information and data described in this version. Downloaded©202 from1 www.aappublications.org/news American Academy byof guest Pediatrics on October 1, 2021 Prepublication Release COVID-19 Associated Pulmonary Embolism in Pediatric Patients Melissa Chima, BS1, Duane Williams, MD2, Neal J. Thomas, MD2,3, Conrad Krawiec, MD2 Authors’ Affiliations and Addresses: 1Penn State College of Medicine, 500 University Drive, P.O. Box 850, Hershey, PA, USA 17033-0850, Tel: (717)-531-5337, Fax: (717)-531-8985.
    [Show full text]
  • Pulmonary Embolism Or Pneumocystis Jiroveci Pneumonia?
    breathe case presentations.qxd 26/07/2006 12:03 Page 5 CASE PRESENTATION Pulmonary embolism or Pneumocystis jiroveci pneumonia? Case report Table 1 Vital signs and F. Braiteh1,2 A 33-year-old male presented to the emergency laboratory test results at I. Nash3 department with a 5-day history of exertional dys- presentation pnoea, dry cough, lethargy and an ongoing fever of 38.9°C. He had been previously diagnosed Investigation Result Normal 1Medical Oncology, Division of with left-frontal oligodendroglioma during a range Cancer Medicine, The University work-up following a new-onset seizure 4 months Vital signs of Texas M.D. Anderson Cancer Temperature °C 36.6 earlier. After successful tumour resection and Center, 2University of Texas Respiratory rate cycles·min-1 22 adjuvant radiotherapy, the patient totally recov- Graduate School of Biomedical Heart rate beats·min-1 88 ered without any residual paresis. He was main- Sciences, Houston, TX, and Blood pressure mmHg 126/64 3Dept of Pathology, Hospital of tained on valproic acid and dexamethasone at a O2 saturation % 91 Saint Raphael, Yale School of -1 dose that was tapered down to 2 mg·day . Haematological counts and coagulation Medicine, New Haven, CT, USA. The physical examination was unremarkable. White cells ×109·L -1 6.8 4.0–10.0 The patient was haemodynamically stable but Platelets ×109·L -1 123 150–350 hypoxaemic and anaemic (table 1). Chest radio- Haemoglobin g·dL-1 9.3 12.0–16.0 Correspondence: graphy and computed tomography (CT) were Prothrombine time s 12.8 <13.0 F.
    [Show full text]
  • Pulmonary Embolism (Pe): Diagnosis
    PULMONARY EMBOLISM (PE): DIAGNOSIS OBJECTIVE: To provide a diagnostic approach to patients with suspected acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE), which comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common disease, affecting approximately 1-2 in 1,000 adults per year. The diagnosis of PE has increased significantly since the advent of computed tomography pulmonary angiography (CTPA) with its widespread availability and enhanced sensitivity. The majority of PE originates in the proximal deep veins of the leg, despite the observation that only 25-50% of patients with PE have clinically evident DVT at the time of PE diagnosis. While active malignancy, surgery (especially orthopedic), hospitalization, air travel >8 hours, and hormone use/pregnancy are common transient provoking factors, approximately 50% of first-time PEs appear to be unprovoked. Symptoms of PE may include sudden onset dyspnea, pleuritic chest pain, and syncope. Signs of PE may include tachypnea, tachycardia, hypoxemia, hypotension, and features of right ventricular dysfunction (distended jugular veins). There may be accompanying signs and symptoms of DVT. The ECG may show right ventricular strain (S1Q3T3, right bundle branch block and T-inversion in leads V1- V4). Up to 10% of symptomatic PEs are fatal within the first hour of symptom onset. Independent predictors of mortality within the first few days after diagnosis of PE include hypotension (systolic blood pressure [SBP] <90 mmHg), clinical right heart failure, right ventricular dilatation on CTPA/echocardiography, positive troponin, and elevated brain natriuretic peptide (BNP). Early diagnosis and treatment of PE reduces morbidity and mortality. DIAGNOSIS OF PE: The constellation of symptoms and signs may be suggestive of PE but do not alone have the sensitivity or specificity to rule in or rule out the diagnosis.
    [Show full text]
  • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
    How can it be prevented? You can take steps to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). If you're at risk for these conditions: • See your doctor for regular checkups. • Take all medicines as your doctor prescribes. • Get out of bed and move around as soon as possible after surgery or illness (as your doctor recommends). Moving around lowers your chance of developing a blood clot. References: • Exercise your lower leg muscles during Deep Vein Thrombosis: MedlinePlus. (n.d.). long trips. Walking helps prevent blood Retrieved October 18, 2016, from clots from forming. https://medlineplus.gov/deepveinthrombos is.html If you've had DVT or PE before, you can help prevent future blood clots. Follow the steps What Are the Signs and Symptoms of Deep above and: Vein Thrombosis? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from • Take all medicines that your doctor http://www.nhlbi.nih.gov/health/health- prescribes to prevent or treat blood clots topics/topics/dvt/signs • Follow up with your doctor for tests and treatment Who Is at Risk for Deep Vein Thrombosis? - • Use compression stockings as your DEEP NHLBI, NIH. (n.d.). Retrieved October 18, doctor directs to prevent leg swelling 2016, from http://www.nhlbi.nih.gov/health/health- VEIN topics/topics/dvt/atrisk THROMBOSIS How Can Deep Vein Thrombosis Be Prevented? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from (DVT) http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/prevention How Is Deep Vein Thrombosis Treated? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/treatment Trinity Surgery Center What is deep vein Who is at risk? What are the thrombosis (DVT)? The risk factors for deep vein thrombosis symptoms? (DVT) include: Only about half of the people who have DVT A blood clot that forms in a vein deep in the • A history of DVT.
    [Show full text]
  • Modern Management of Traumatic Hemothorax
    rauma & f T T o re l a t a m n r e u n o t J Mahoozi, et al., J Trauma Treat 2016, 5:3 Journal of Trauma & Treatment DOI: 10.4172/2167-1222.1000326 ISSN: 2167-1222 Review Article Open Access Modern Management of Traumatic Hemothorax Hamid Reza Mahoozi, Jan Volmerig and Erich Hecker* Thoraxzentrum Ruhrgebiet, Department of Thoracic Surgery, Evangelisches Krankenhaus, Herne, Germany *Corresponding author: Erich Hecker, Thoraxzentrum Ruhrgebiet, Department of Thoracic Surgery, Evangelisches Krankenhaus, Herne, Germany, Tel: 0232349892212; Fax: 0232349892229; E-mail: [email protected] Rec date: Jun 28, 2016; Acc date: Aug 17, 2016; Pub date: Aug 19, 2016 Copyright: © 2016 Mahoozi HR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Hemothorax is defined as a bleeding into pleural cavity. Hemothorax is a frequent manifestation of blunt chest trauma. Some authors suggested a hematocrit value more than 50% for differentiation of a hemothorax from a sanguineous pleural effusion. Hemothorax is also often associated with penetrating chest injury or chest wall blunt chest wall trauma with skeletal injury. Much less common, it may be related to pleural diseases, induced iatrogenic or develop spontaneously. In the vast majority of blunt and penetrating trauma cases, hemothoraces can be managed by relatively simple means in the course of care. Keywords: Traumatic hemothorax; Internal chest wall; Cardiac Hemodynamic response injury; Clinical manifestation; Blunt chest-wall injuries; Blunt As above mentioned the hemodynamic response is a multifactorial intrathoracic injuries; Penetrating thoracic trauma response and depends on severity of hemothorax according to its classification.
    [Show full text]
  • Treatment of Hemothorax in the Era Of€The€Minimaly Invasive Surgery
    Mil. Med. Sci. Lett. (Voj. Zdrav. Listy) 2019, 88(4), 180-187 ISSN 0372-7025 (Print) ISSN 2571-113X (Online) DOI: 10.31482/mmsl.2019.011 Since 1925 REVIEW ARTICLE TREATMENT OF HEMOTHORAX IN THE ERA OF THE MINIMALY INVASIVE SURGERY Radek Pohnán 1,2 , Šárka Blažková 2, Vladislav Hytych 2, Petr Svoboda 1, Michal Makeľ 1, Iva Holmquist 3,4 and Miroslav Ryska 1 1 Department of Surgery, Central Military Hospital – Faculty Military Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic 2 Department of Thoracic Surgery, Thomayer's Hospital, 140 59 Prague, Czech Republic 3 Emory University Hospital Midtown, Maternity Center, Atlanta, Georgia, USA 4 Department of Epidemiology, Faculty of Health Sciences, University of Defence, Hradec Kralove, Czech Republic Received 19th July 2018. Accepted 13th May 2019. On-line 6th December 2019. Summary Hemothorax is a frequent clinical situation often associated with chest injury or with iatrogenic lesions. Spontaneous hemothorax is uncommon and among its cause may include coagulation disorders, pleural, pulmonary or vascular pathology. Diagnostics is based on radiography or ultrasound and thoracentesis which may be also therapeutic solution. The majority of hemothoraxes can be managed non-operatively but hemodynamic instability, the volume of evacuated blood and persisting blood loss or persisting hemothorax require surgery. A surgical approach may vary from open thoracotomy to rapidly developing minimally invasive methods - video-assisted thoracoscopic surgery (VATS) and videothoracoscopy (VTS). Key words: hemothorax; surgery; VATS; thoracotomy Introduction Hemothorax is a pathological collection of the blood within the pleural cavity. Hemothorax most frequently origin in a thoracic injury but the exact incidence is not known.
    [Show full text]
  • COVID19 and Pulmonary Embolism
    COVID19 and Pulmonary Embolism Timothy Morris, MD Pulmonary/Critical Care, University of California, San Diego Timothy Fernandes, MD Pulmonary/Critical Care, University of California, San Diego Richard Channick, MD Pulmonary/Critical Care, University of California, Los Angeles Victor Tapson, MD Pulmonary and Critical Care, Cedars-Sinai Nicolas Gallastegui Crestani, MD Hematology, University of California, San Diego Daniel Bond, MD Pulmonary/Critical Care, University of California, San Diego COVID19 • Pathological features • Macro vs Micro • Serological markers • Epidemiology • Case presentations COVID19 • Pathological features • Macro vs Micro • Serological markers • Epidemiology • Case presentations Alveolar fibrin in COVID19-ARDS (like most ARDS) 1. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681-686. Small in situ thrombosis in COVID19-ARDS 1. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681-686. Big RV dilatation in COVID19-ARDS 1. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681-686. In situ arteriolar thrombosis in COVID19-ARDS Platelet IIIa stain megakaryocyte 1. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.
    [Show full text]